The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: -1.00 (-2.15%)
Spread: 1.00 (2.222%)
Open: 46.50
High: 45.50
Low: 45.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Avacta Group narrows loss as revenues rise

Mon, 17th Oct 2016 10:54

(ShareCast News) - Biotherapeutic, research and diagnostic reagent developer Avacta Group announced its preliminary results for the year to 31 July on Monday, with revenues and losses in line with market expectations.The AIM-traded company said it was well funded at period end, with cash balances of £19.52m.Group revenues increased 19% to £2.17m during the year, with Avacta Life Sciences revenue improving to £0.7m from £0.44m, and Avacta Animal Health revenue up to £1.46m from £1.37m.Its loss from continuing operations narrowed to £4.65m, from £4.89m a year ago, and the total loss for the period more than halved to £4.65m from £9.99m.Avacta's loss per share reduced to 6.86p from 20.09p."We have made excellent progress in our strategy to commercialise Affimer reagents for research, diagnostics and therapeutics," said group chief executive Alastair Smith."There are a significant number of Affimer technology evaluations ongoing and we continue to grow our pipeline of partnerships that will ultimately deliver a stream of 'Affimer-powered' products to help underpin long term revenue growth from non-therapeutic applications."Smith said positive results from the first animal safety and efficacy studies with the company's Affimer therapeutic programmes were an important milestone for Avacta."They significantly de-risk the Affimer technology as a therapeutic platform, demonstrating that Affimers have the right properties to be drugs in terms of serum half-life, functionality and efficacy in vivo."We have strengthened our belief that Affimers have the potential to become an important new class of biological drug that could eventually rival antibodies."Smith explained that the company was pleased with the success of its programme to develop specific Affimer binders to the Zika NS-1 protein, as it was a good example of the speed with which high quality Affimer reagents can be developed to answer an urgent need where there is a gap in the antibody offering."We are very optimistic about 2017 and I look forward to updating the market as we develop these and other products further with clinical and commercial partners."
More News
1 Sep 2022 12:01

Avacta cancer drug candidate AVA6000 advances to fourth dose cohort

(Alliance News) - Avacta Group PLC said on Wednesday its candidate for multiple forms of cancer, AVA6000 Pro-doxorubicin, is advancing to its fourth dose cohort.

Read more
21 Jul 2022 15:29

Avacta joint venture completes fresh funding round

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Thursday that AffyXell, its joint venture with Daewoong Pharmaceuticals, has completed a funding round to advance its lead mesenchymal stem cell (MSC) programme towards the clinic, and to develop its wider preclinical pipeline of cell therapies.

Read more
21 Jul 2022 12:17

Avacta joint venture completes funding for lead cell therapy programme

(Alliance News) - Avacta Group PLC on Thursday said that its joint venture AffyXell with Daewoong Pharmaceuticals Co Ltd has successfully completed a funding round.

Read more
30 Jun 2022 11:22

Avacta's partner LG Chem renews licence to develop Affimer platform

(Alliance News) - Avacta Group PLC said on Thursday that LG Chem Life Sciences has exercised its renewal option as part of an ongoing collaboration with the company, triggering a fee payment of USD2 million to Avacta.

Read more
29 Jun 2022 11:38

AIM WINNERS & LOSERS: Deltic rises on Shell deal; Windar down on delay

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
29 Jun 2022 10:21

Avacta shares up as cancer drug AVA6000 advances to third dose cohort

(Alliance News) - Avacta Group PLC said on Wednesday its candidate for multiple forms of cancer, AVA6000 Pro-doxorubicin, is advancing to its third dose cohort after "a positive review of the safety data" from the second cohort.

Read more
16 Jun 2022 16:03

UK shareholder meetings calendar - next 7 days

Friday 17 June 
Blackstone Loan Financing LtdAGM
boohoo Group PLCAGM
Directa Plus PLCAGM
Tesco PLCAGM
EnQuest PLCAGM
Octopus Renewables Infrastructure Trust PLCAGM
Monday 20 June 
Armadale Capital PLCAGM
Bank of Georgia Group PLCAGM
Globalworth Real Estate Investments LtdAGM
MetalNRG PLCAGM
Midatech Pharma PLCAGM
Silver Bullet Data Services Group PLCGM re fundraise
Venture Life Group PLCAGM
Tuesday 21 June 
1Spatial PLCAGM
Altus Strategies PLCAGM
Coca-Cola HBC AGAGM
FireAngel Safety Technology Group PLCAGM
HC Slingsby PLCAGM
HSS Hire Group PLCAGM
Mission Group PLCAGM
Novacyt SAAGM
Pendragon PLCAGM
RTW Venture Fund LtdAGM
Velocys PLCAGM
Wednesday 22 June 
ASA International Group PLCAGM
Atalaya Mining PLCAGM
Bonhill Group PLCAGM
Chapel Down Group PLCAGM
Churchill China PLCAGM
Downing Renewables & Infrastructure Trust PLCGM re share issue
Ecofin US Renewables Infrastructure Trust PLCAGM
EJF Investments LtdAGM
Frenkel Topping Group PLCAGM
Good Energy Group PLCAGM
Honeycomb Investment Trust PLCAGM
ICG-Longbow Senior Secured UK Property Debt Investments LtdAGM
Intelligent Ultrasound Group PLCAGM
Iofina PLCAGM
John Wood Group PLCAGM
Kingfisher PLCAGM
LXi REIT PLCGM
Menhaden PLCAGM
North Atlantic Smaller Cos Investment Trust PLCAGM
Pennant International Group PLCAGM
Plant Health Care PLCAGM
Skillcast Group PLCAGM
Team PLCAGM
Tribal Group PLCGM re final dividend
Trident Royalties PLCAGM
Vertu Motors PLCAGM
Wentworth Resources PLCAGM
Thursday 23 June 
Avacta Group PLCAGM
Anglo Asian Mining PLCAGM
Card Factory PLCAGM
Cordiant Digital Infrastructure LtdAGM
Downing Renewables & Infrastructure Trust PLCGM re initial placing & open offer
Eight Capital Partners PLCGM re aligning 2022 bonds with 2026 bonds
GENinCode PLCAGM
Ideagen PLCGM re takeover by Hg Pooled Management Ltd
Longboat Energy PLCAGM
Oxford Nanopore Technologies PLCAGM
Puma VCT 13 PLCGM re cancellation of listing & liquidation
RBG Holdings PLCAGM
Tandem Group PLCAGM
Zinnwald Lithium PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
16 May 2022 14:04

IN BRIEF: Avacta joint venture expands partnership with GenScript

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Says its joint venture AffyXell with Seoul, South Korea-based drug maker Daewoong Pharmaceutical Co Ltd expanded its partnership with GenScript ProBio. Says the partnership covers the process development and production of viral vectors required for the production of AffyXell's future cell therapy products. Adds that GenScript has now committed to take an equity position in AffyXell at a future funding round. The two companies will also collaborate in the area of business development, including potential out-licensing.

Read more
13 Apr 2022 17:33

Avacta increases shareholding in drug developer AffyXell to 22%

(Alliance News) - Avacta Group PLC said on Wednesday it increased its shareholding in its South Korean joint venture, AffyXell Therapeutics.

Read more
13 Apr 2022 13:57

Avacta triggers milestone in Daewoong joint venture

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Wednesday that a milestone equity payment has been triggered, resulting in an increase in its shareholding in AffyXell Therapeutics.

Read more
8 Apr 2022 16:17

Avacta joint venture enters new immune model collaboration

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Friday that AffyXell Therapeutics - its joint venture with Daewoong Pharmaceutical - has entered into a collaboration agreement with Chinese biological drugs developer Biocytogen and the Korea Non-Clinical Technology Solution Center (KNTSC).

Read more
8 Apr 2022 11:28

AIM WINNERS & LOSERS: Sensyne Health drops amid AIM delisting warning

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
8 Apr 2022 10:37

Avacta joint venture to collaborate with Chinese biological company

(Alliance News) - Avacta Group PLC said on Friday its joint venture has found a Chinese collaborator to develop new biologic drugs.

Read more
6 Apr 2022 10:23

IN BRIEF: Avacta widens annual loss on research, manufacturing costs

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Posts widened loss in 2021. Pretax loss expands to GBP29.2 million from GBP18.9 million in 2020. However, revenue rises to GBP2.9 million from GBP2.1 million. Like the year before, there will be no dividends.

Read more
16 Mar 2022 13:02

Avacta offloads animal health unit in £2.3m deal

(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that Vimian Group has acquired its veterinary division, Avacta Animal Health, for consideration of up to £2.3m.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.